Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal residual disease detection in Chinese patients with multiple myelomaInvivoscribe Marketing2024-03-26T13:50:51-07:00March 19th, 2024|Read more
Quantification of Measurable Residual Disease Detection by Next-Generation Sequencing–Based Clonality Testing in B-Cell and Plasma Cell NeoplasmsInvivoscribe Marketing2024-03-03T11:41:21-08:00March 1st, 2024|Read more
Leveraging Standardized MRD Assays to Guide CLL Treatmentwmm2024-01-25T10:44:11-08:00January 25th, 2024|Read more
Clonal Characterization and Somatic Hypermutation Assessment by Next-Generation Sequencing in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomawmm2023-04-10T20:22:16-07:00March 23rd, 2023|Read more
DNA Sequencing to Detect Residual Disease in Adults With Acute Myeloid Leukemia Prior to Hematopoietic Cell TransplantInvivoscribe Marketing2024-08-02T14:22:45-07:00March 7th, 2023|Read more
Invivoscribe Announces Updated Reimbursement for the LeukoStrat CDx FLT3 Mutation Assay to Select Newly Diagnosed FLT3-ITD Positive AML Patients Eligible for VANFLYTA in JapanInvivoscribe Marketing2023-05-25T17:09:22-07:00May 25th, 2023|Read more
Invivoscribe Announces IVDR Approval of the LeukoStrat CDx FLT3 Mutation AssayInvivoscribe Marketing2023-05-11T03:12:47-07:00May 11th, 2023|Read more
Invivoscribe Diagnostic Technologies (Shanghai) Co. Ltd. Receives CAP Accreditation to Support Clinical Research Testing for Pharmaceutical Partners in ChinaInvivoscribe Marketing2023-02-23T06:28:40-08:00February 23rd, 2023|Read more
Invivoscribe Appoints Masato Sasaki as General Manager of LabPMM, GK (Japan)Invivoscribe Marketing2023-02-01T21:02:16-08:00February 1st, 2023|Read more
Invivoscribe files sPMA with the FDA for use of the LeukoStrat CDx FLT3 Mutation Assay to Select Patients with Newly Diagnosed FLT3-ITD Positive AMLwmm2022-10-24T14:57:12-07:00October 24th, 2022|Read more